News | May 25, 2021
Bal Pharma launches BALflu, Favipiravir formulation in India
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
The company had filed a suit in the High Court of Justice, Ghana
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
Subscribe To Our Newsletter & Stay Updated
